Ebook

Regulatory Considerations For Cell and Gene Therapies

Chemistry, Manufacturing and Controls (CMC) issues often relate to starting and ancillary materials, manufacturing processes, and process/ quality control.

Company Logo

Released By Cardinal Health

Cell and Gene Therapy: CMC Challenges and Mitigation Strategies
Novel technologies, complex manufacturing and accelerated development timelines make CMC critical for CGT products.
Read More >>

Eliminating Endotoxins – Reagent Quality Testing for Cell and Gene Therapies
The importance of reagent quality control, especially endotoxin testing, during CGT development and the selection of reagents and suppliers to ensure safety.
Read More >>

Cell & Gene Therapy Delivery Devices
A Q&A with Cardinal Health’s Mathew Varkey, Supervisor, Regulatory Submissions Operations.
Read More >>

Earning RMAT Designation
What developers need to know
Read More >>

An Introduction to Phase-Appropriate CGMP Considerations for Cell and Gene Therapy
Readiness to begin GMP manufacturing is a decision point that requires careful consideration.
Read More >>


Request more information from Cardinal Health

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters